Literature DB >> 10910933

Triose phosphate isomerase deficiency in 3 French families: two novel null alleles, a frameshift mutation (TPI Alfortville) and an alteration in the initiation codon (TPI Paris).

C Valentin1, S Pissard, J Martin, D Héron, P Labrune, M O Livet, M Mayer, T Gelbart, A Schneider, I Max-Audit, M Cohen-Solal.   

Abstract

Three French families with triose phosphate isomerase (TPI) deficiency were studied, and 2 new mutations giving rise to null alleles were observed: a frameshift mutation with deletion of the 86-87 TG dinucleotide in codon 29 (TPI Alfortville) and a T-->A transversion in nucleotide 2 of the initiation codon (TPI Paris). The first mutation occurred in compound heterozygosity with the frequent E105D mutation. The second mutation occurred in association with the 2-nucleotide promoter variant (-43G,-46A). In a third family, the propositus was an E105D homozygote. In the TPI Paris family, the coinheritance of the -43,-46 promoter variant appeared to exert little, if any, effect on TPI enzyme activity, a finding consistent with 2 previous reports that questioned the putative role of the promoter polymorphism as a true deficiency variant. Similarly, the further coinheritance of glucose-6-phosphate dehydrogenase (G6PD) A- (202 G-->A/376 A-->G) appeared to have little effect on the observed phenotype. Compound heterozygosity for the E105D mutation with the null allele TPI Alfortville appeared to lead to a more severe clinical syndrome than did E105D homozygosity, suggesting that compound heterozygosity with null alleles may lead to more profound clinical abnormalities than homozygosity with missense alleles. A simple, rapid polymerase chain reaction and restriction enzyme procedure for the E105D mutation was developed for prenatal diagnosis in one family and subsequently used for screening in the other families.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10910933

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Drosophila model of human inherited triosephosphate isomerase deficiency glycolytic enzymopathy.

Authors:  Alicia M Celotto; Adam C Frank; Jacquelyn L Seigle; Michael J Palladino
Journal:  Genetics       Date:  2006-09-15       Impact factor: 4.562

2.  Missense variant in TPI1 (Arg189Gln) causes neurologic deficits through structural changes in the triosephosphate isomerase catalytic site and reduced enzyme levels in vivo.

Authors:  Bartholomew P Roland; Kristen R Richards; Stacy L Hrizo; Samantha Eicher; Zackery J Barile; Tien-Chien Chang; Grace Savon; Paola Bianchi; Elisa Fermo; Bianca Maria Ricerca; Luca Tortorolo; Jerry Vockley; Andrew P VanDemark; Michael J Palladino
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-05-07       Impact factor: 5.187

3.  Metabolomics analysis of Cistus monspeliensis leaf extract on energy metabolism activation in human intestinal cells.

Authors:  Yoichi Shimoda; Junkyu Han; Kiyokazu Kawada; Abderrazak Smaoui; Hiroko Isoda
Journal:  J Biomed Biotechnol       Date:  2012-03-18

4.  Triose phosphate isomerase deficiency is caused by altered dimerization--not catalytic inactivity--of the mutant enzymes.

Authors:  Markus Ralser; Gino Heeren; Michael Breitenbach; Hans Lehrach; Sylvia Krobitsch
Journal:  PLoS One       Date:  2006-12-20       Impact factor: 3.240

5.  Initiation codon mutation in betaB1-crystallin (CRYBB1) associated with autosomal recessive nuclear pulverulent cataract.

Authors:  Esther Meyer; Fatimah Rahman; Jessica Owens; Shanaz Pasha; Neil V Morgan; Richard C Trembath; Edwin M Stone; Anthony T Moore; Eamonn R Maher
Journal:  Mol Vis       Date:  2009-05-18       Impact factor: 2.367

6.  Bone marrow transplantation corrects haemolytic anaemia in a novel ENU mutagenesis mouse model of TPI deficiency.

Authors:  Ashlee J Conway; Fiona C Brown; Elinor J Hortle; Gaetan Burgio; Simon J Foote; Craig J Morton; Stephen M Jane; David J Curtis
Journal:  Dis Model Mech       Date:  2018-05-21       Impact factor: 5.758

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.